http://web.archive.org/web/20090427200003id_/http://edition.cnn.com:80/2009/BUSINESS/04/20/gsk.stiefel.sale/

@entity1 , @entity0 has agreed to buy independent @entity6 skincare specialist @entity4 for up to $ 3.6 billion			1
the new business will operate under the @entity4 identity within the @entity9			1
in a statement monday , the two companies said the deal would create a new world - leading specialist dermatology business with combined revenues of $ 1.5 billion			1
under the terms of the agreement @entity3 will acquire the total share capital of @entity4 for $ 2.9 billion			1
@entity3 also expects to assume $ 400 million of net debt upon closing			0
a further $ 300 million cash payment will be made depending on future performance			0
@entity3 's existing prescription dermatological products will be combined with @entity4 's and the new specialist global business will operate under the @entity4 identity within the @entity9			1
the new business will have a broad portfolio of dermatology products including @entity4 's leading brands : @entity33 , for acne , @entity28 for dermatitis and @entity30 for the treatment of severe psoriasis			2
@entity3 's key dermatology brands include : @entity35 , @entity36 and the recently launched @entity37			2
@entity4 , part - owned by buyout firm @entity38 , is the world 's largest independent dermatology company , with a range of prescription and over-the - counter products			1
according to reuters.com it was put up for sale a month ago and attracted interest from a number of large pharmaceutical companies , including @entity49 and @entity50			0
following the announcement , @entity3 chief executive @entity51 said : " as part of our strategy to grow and diversify @entity3 's business , we are continuing to make new investments through targeted acquisitions			0
this transaction will create a new world - leading , specialist dermatology business and re-energize our existing dermatology products			0
" the addition of @entity4 's broad portfolio will provide immediate new revenue flows to @entity3 with significant opportunities to enhance growth through leveraging our existing global commercial infrastructure and manufacturing capability			2
we look forward to working with @entity4 to develop this exciting opportunity			0

@entity3 is the world 's second - largest drugmaker
@entity6 - based @entity4 is world 's largest independent dermatology company
@entity3 will acquire total share capital of @entity4 for $ 2.9 billion
global business will operate under @entity4 identity within @entity9

@entity3:GSK
@entity2:CNN
@entity1:LONDON
@entity0:England
@entity35:Bactroban
@entity6:U.S.
@entity37:Altabax
@entity4:Stiefel
@entity38:Blackstone Group
@entity9:GSK Group
@entity36:Cutivate
@entity33:Duac
@entity51:Andrew Witty
@entity50:Johnson & Johnson
@entity30:Soriatane
@entity49:Novartis
@entity28:Olux E